Acetonylacetone


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D001259 Ataxia PMID:31760062; PMID:32860822
MESH:D001930 Brain Injuries PMID:19464574
MESH:D009133 Muscular Atrophy PMID:225920
MESH:D009336 Necrosis PMID:6827287
MESH:D009410 Nerve Degeneration PMID:19033394; PMID:225920; PMID:32522579
MESH:D009422 Nervous System Diseases PMID:12164553; PMID:1387790
MESH:D010243 Paralysis PMID:31760062
MESH:D010523 Peripheral Nervous System Diseases PMID:171344; PMID:225920
MESH:D013733 Testicular Diseases PMID:1288759; PMID:17725299
MESH:D015431 Weight Loss PMID:19033394; PMID:32860822
MESH:D018908 Muscle Weakness PMID:19033394; PMID:225920
MESH:D019636 Neurodegenerative Diseases PMID:17492505
MESH:D020233 Gait Disorders, Neurologic PMID:19033394
MESH:D020258 Neurotoxicity Syndromes PMID:19033394
MESH:D053627 Asthenozoospermia PMID:10689203
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:2361581
MESH:D064420 Drug-Related Side Effects and Adverse Reactions PMID:1288759

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.